An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases

被引:151
作者
Heng, Boon Chin [1 ]
Aubel, Dominique [1 ,2 ]
Fussenegger, Martin [1 ,3 ]
机构
[1] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, CH-4058 Basel, Switzerland
[2] Univ Lyon 1, IUTA Dept Genie Biol, F-69622 Villeurbanne, France
[3] Univ Basel, Fac Sci, CH-4058 Basel, Switzerland
关键词
G-protein; Disease; Human; Molecular; Pathology; Receptor; MELANIN-CONCENTRATING-HORMONE; GROWTH-FACTOR RECEPTOR; METABOTROPIC GLUTAMATE RECEPTORS; ADENOSINE A(2A) RECEPTORS; ANGIOTENSIN-II RECEPTORS; GLUCAGON-LIKE PEPTIDE-1; DOPA-INDUCED DYSKINESIA; HISTAMINE H-4 RECEPTOR; FATTY-ACID RECEPTORS; NF-KAPPA-B;
D O I
10.1016/j.biotechadv.2013.08.017
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
G-protein coupled receptots (GPCRs) modulate diverse cellular responses to the majority of neurotransmitters and hormones within the human body. They exhibit much structural and functional diversity, and are responsive to a plethora of endogenous (biogenic amines, cations, lipids, peptides, and glycoproteins) and exogenous (therapeutic drugs, photons, tastants, and odorants) ligands and stimuli. Due to the key roles of GPCRs in tissue/cell physiology and homeostasis, signaling pathways associated with GPCRs are implicated in the pathophysiology of various diseases, ranging from metabolic, immunological, and neurodegenerative disorders, to cancer and infectious diseases. Approximately 40% of clinically approved drugs mediate their effects by modulating GPCR signaling pathways, which makes them attractive targets for drug screening and discovery. The pace of discovery of new GPCR-based drugs has recently accelerated due to rapid advancements in high-resolution structure determination, high-throughput screening technology and in silico computational modeling of GPCR binding interaction with potential drug molecules. This review aims to provide an overview of the diverse roles of GPCRs in the pathophysiology of various diseases that are the major focus of biopharmaceutical research as potential drug targets. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:1676 / 1694
页数:19
相关论文
共 349 条
  • [1] The resurgence of A2B adenosine receptor signaling
    Aherne, Carol M.
    Kewley, Emily M.
    Eltzschig, Holger K.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2011, 1808 (05): : 1329 - 1339
  • [2] Effect of neuropeptide B on feeding behavior is influenced by endogenous corticotropin-releasing factor activities
    Aikawa, Shizu
    Ishii, Makoto
    Yanagisawa, Masashi
    Sakakibara, Yuzuru
    Sakurai, Takeshi
    [J]. REGULATORY PEPTIDES, 2008, 151 (1-3) : 147 - 152
  • [3] Chemokines: novel targets for breast cancer metastasis
    Ali, Simi
    Lazennec, Gwendal
    [J]. CANCER AND METASTASIS REVIEWS, 2007, 26 (3-4) : 401 - 420
  • [4] Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial
    Anand, I
    McMurray, J
    Cohn, JN
    Konstam, MA
    Notter, T
    Quitzau, K
    Ruschitzka, F
    Lüscher, TF
    [J]. LANCET, 2004, 364 (9431) : 347 - 354
  • [5] Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy
    Andrade, Daniele
    Serra, Rafaela
    Svensjoe, Erik
    Lima, Ana Paula C.
    Ramos Junior, Erivan S.
    Fortes, Fabio S.
    Morandini, Ana Carolina F.
    Morandi, Veronica
    Soeiro, Maria de N.
    Tanowitz, Herbert B.
    Scharfstein, Julio
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (05) : 1333 - 1347
  • [6] CB2 cannabinoid receptors as an emerging target for demyelinating diseases:: from neuroimmune interactions to cell replacement strategies
    Arevalo-Martin, A.
    Garcia-Ovejero, D.
    Gomez, O.
    Rubio-Araiz, A.
    Navarro-Galve, B.
    Guaza, C.
    Molina-Holgado, E.
    Molina-Holgado, F.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (02) : 216 - 225
  • [7] A CB1/CB2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin
    Arevalo-Martin, Angel
    Molina-Holgado, Eduardo
    Guaza, Carmen
    [J]. NEUROPHARMACOLOGY, 2012, 63 (03) : 385 - 393
  • [8] Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion
    Arora, P.
    Cuevas, B. D.
    Russo, A.
    Johnson, G. L.
    Trejo, J.
    [J]. ONCOGENE, 2008, 27 (32) : 4434 - 4445
  • [9] Altered expression of endothelin receptors in failing human left ventricles
    Asano, K
    Bohlmeyer, TJ
    Westcott, JY
    Zisman, LS
    Kinugawa, K
    Good, M
    Minobe, WA
    Roden, RL
    Wolfel, EE
    Lindenfeld, J
    Port, JD
    Perryman, MB
    Cleveland, J
    Lowes, BD
    Bristow, MR
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2002, 34 (07) : 833 - 846
  • [10] Ashton JC, 2007, CURR OPIN INVEST DR, V8, P373